ADVANTAGES AND DISADVANTAGES OF WARFARIN AND PRADAXA THERAPY FOR VENOUS THROMBOEMBOLISM

• Main Authors: B. S. Sukovatykh, L. N. Belikov, O. F. Savchuk, M. B. Sukovatykh
• Format: Article
• Language: Russian
• Published: Pavlov First Saint Petersburg State Medical University 2018-01-01
• Series: Вестник хирургии имени И.И. Грекова
• Subjects: прадакса (дабигатран); варфарин; венозный тромбоэмболизм; pradaxa (dabigatran); warfarin; venous thromboembolism
• Online Access: https://www.vestnik-grekova.ru/jour/article/view/561

An analysis of complex examination of 110 patients with venous thromboembolism was made. The patients were separated into 2 groups. The first group included 60 patients, who had the start heparin therapy during 7 days with the following 6-month warfarin therapy. Warfarin was substituted by pradaxa (dabigatran) for 50 patients of the second group. The efficacy of pradaxa could be compared with warfarin. However, pradaxa had a number of advantages such as the predictable anticoagulant effect, standard dosages. This medicine is more predictable and doesn’t require a control of homeostasis and an adjustment of drug dosage.